Slide 1: Hyperphagia and Body Weight Gain Are Reduced With Once-Weekly Treatment With RM-718
Hyperphagia and Body Weight Gain Are Reduced With Once-Weekly Treatment With RM-718, a Selective Melanocortin-4 Receptor Agonist, in Zucker Obese Rats Danica Grujic, PhD1; Bhavik P. Shah, PhD1,2; Vito LaVopa, PhD1; Srishty Subramanian, PhD1; Jill C. Garrison, PhD1; Christian L. Roth, MD3,4 1Rhythm P
Slide 2: New Generation of a Selective MC4R agonist, RM-718
New Generation of a Selective MC4R agonist, RM-718 • Hypothalamic MC4R signaling regulates hunger, satiety, and energy expenditure; impairments in the MC4R pathway can cause hyperphagia and early- or rapid-onset, severe obesity1-4 • Setmelanotide, an MC4R agonist, reduces hunger and weight in patien
Slide 3: RM-718 Demonstrated Reduction in Body Weight and Food Intake
RM-718 Demonstrated Reduction in Body Weight and Food Intake • 21-day parallel study of 4 arms (n=8): placebo, setmelanotide 5 mg/kg QW, RM-718 5 mg/kg QW, and RM-718 10 mg/kg QW Body Weight Normalization of Food Intake Placebo Setmelanotide 5 mg/kg QW RM-718 5 mg/kg QW RM-718 10 mg/kg QW Placebo Se
Slide 4: RM-718 Reduces Insulin Levels and Fat Mass
RM-718 Reduces Insulin Levels and Fat Mass Insulin Sensitivity Improvement Carcass Fat and Protein Mass Fat Protein 350 300 55 Total mass, g 250 53 54 50 200 150 266 100 223 226 225 50 0 Placebo Setmelanotide RM-718 RM-718 5 mg/kg QW 5 mg/kg QW 10 mg/kg QW Percent Fat mass −16* −15* −15* change vs p
Slide 5: Summary and Conclusions
Summary and Conclusions • Three weeks of RM-718 QW was well tolerated and led to sustained reduction of hyperphagia, body weight, and fat mass with no changes in lean mass in Zucker obese rats; treatment also led to improved insulin sensitivity similar to that observed with setmelanotide • A separat